Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

By Tarun Sai Lomte A four-week treatment with oral vancomycin led to clinical remission in PSC-IBD patients, accompanied by ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

An antibiotic used to treat infective diarrhoea may be an effective drug for a type of inflammatory bowel disease, according ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...

Overall, 23 PSC-IBD cases (32%) underwent OLT for treatment of PSC. Of these, six (26% ... In this referral centre based study, inflammatory bowel disease associated with primary sclerosing ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).